8-bromo-beta-phenyl-1-n(2)-ethenoguanosine-3--5--cyclic-monophosphorothioate has been researched along with Disease-Models--Animal* in 1 studies
1 other study(ies) available for 8-bromo-beta-phenyl-1-n(2)-ethenoguanosine-3--5--cyclic-monophosphorothioate and Disease-Models--Animal
Article | Year |
---|---|
Investigating the role of protein kinase-G in the antidepressant-like response of sildenafil in combination with muscarinic acetylcholine receptor antagonism.
The cGMP/PK-G pathway plays a crucial role in neuroprotection and neurotrophin support, and is possibly involved in antidepressant action. Recently we reported on a novel antidepressant-like response following simultaneous administration of sildenafil (phosphodiesterase 5 (PDE5) inhibitor, thereby increasing cGMP levels), and atropine (muscarinic acetylcholine receptor antagonist) in the rat forced swim test (FST). However, it is unclear whether the antidepressant-like activity of sildenafil+atropine is mediated via the activation of PK-G, an important down-stream effector for cGMP, and whether this may target known pathways in antidepressant action. We investigated whether the antidepressant-like response of sildenafil+/-atropine could be reversed by Rp-8-Br-PET-cGMP, a PK-G inhibitor, and also whether a combination of 8-Br-cGMP (PK-G activator)+/-atropine would likewise be active in the FST, and whether this combination could be attenuated by a PK-G inhibitor. 8-Br-cGMP alone, but not sildenafil alone, reduced immobility and selectively increased swimming in the FST. The antidepressant-like action of sildenafil was only evident following co-administration of atropine, and selectively increased climbing behaviour. Importantly, PK-G inhibition prevented the antidepressant-like effects of both 8-Br-cGMP and the sildenafil/atropine combination. These results confirm cholinergic-cGMP-PK-G interactions in the antidepressant-like effects of sildenafil, putatively acting via noradrenergic mechanisms, whereas direct PK-G activation induces antidepressant-like effects that are associated with enhancement of serotonergic neurotransmission. Topics: Animals; Atropine; Behavior, Animal; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Depression; Disease Models, Animal; Drug Administration Routes; Drug Interactions; Drug Therapy, Combination; Freezing Reaction, Cataleptic; Male; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Statistics, Nonparametric; Sulfones; Swimming; Thionucleotides | 2010 |